Results and discussion
We first asked whether Slap is expressed in fibroblasts and whether it associates with the activated PDGF receptor. A polyclonal antibody raised against the carboxyl terminus of Slap recognised Slap in Cos7 cells that had been transfected with an expression vector encoding a haemagglutinin (HA) epitope-tagged version of Slap ( Figure 1a ). In addition, this antibody specifically immunoprecipitated a protein of the same size (34 kDa) from lysates of NIH3T3 fibroblasts, and the antibody also only recognised a single (b) Association of Slap with the activated PDGF receptor. Slap and the PDGF receptor were immunoprecipitated using the antibodies indicated from quiescent NIH3T3 cells treated with or without PDGF. The immunoprecipitated proteins were subjected to SDS-PAGE and then visualised by western blotting using antibodies against Slap (anti-Slap), the PDGF receptor (anti-PDGFR) or phosphotyrosine residues (anti-pTyr). band of 34 kDa when whole cell lysates were probed, demonstrating its specificity for Slap ( Figure 1a ). In quiescent fibroblasts stimulated with PDGF, Slap was associated with the activated PDGF receptor, as revealed by probing both PDGF receptor and Slap immunoprecipitates with the appropriate antibodies ( Figure 1b) . As with the adaptor molecules, Grb2 and Grb10 [2, 3] , the association with the PDGF receptor did not, however, lead to tyrosine phosphorylation of Slap itself.
The predominant site on the PDGF receptor to which cSrc binds is tyrosine 579 (Y579), which is located in the juxtamembrane region; the phosphorylated Y581 residue is also involved in c-Src binding [4] . To determine whether these or other phosphotyrosine residues were critical for engaging Slap, HepG2 cells expressing various PDGF receptor mutants [5] were analysed (Figure 2a ). Slap could still associate with a receptor in which five major tyrosine phosphorylation sites -not including Y579 and Y581 -had been mutated into phenylalanine residues (F5). Slap also associated with the Y581F mutant, but with apparently lower affinity than with the F5 mutant, suggesting that Y579 might be the binding site for Slap. This could not be tested directly, because of the reduced kinase activity of PDGF receptor Y579F mutants [4] .
Instead, a phosphopeptide competition approach was used [6] . A glutathione-S-transferase (GST) fusion protein containing the amino terminus and the SH3 and SH2 domains of Slap -GST-Slap(N,SH3,SH2) -bound to the PDGF receptor in vitro. Addition of a peptide corresponding to the Src-binding site on the PDGF receptor, containing phosphorylated Y579 and Y581 residues, inhibited this binding ( Figure 2b ). Peptides corresponding to binding sites for phosphatidylinositol (PI) 3-kinase, ras GTPase-activating protein (rasGAP) and phospholipase Cγ did not compete. A peptide containing phosphorylated YEEI (pYEEI, the general consensus binding sequence for c-Src [7] ) also abolished the binding of Slap to the PDGF receptor. These data suggest that the Slap SH2 domain has a similar binding specificity to the Src SH2 domain. To test this, Src was immunoprecipitated from a cell lysate of Sf9 insect cells infected with a Src-producing baculovirus, and incubated with baculovirus-produced PDGF receptor protein, in the presence or the absence of purified GST fusion proteins, as indicated in Figure 2c . GST-Slap competed efficiently with Src for PDGF receptor binding. GST alone, a Slap construct deleted in the SH2 domain -GST-Slap(N,SH3) -and a GST construct containing the SH2 and SH3 domains of rasGAP -GST-GAP(SH2,SH3,SH2) -did not compete for binding, however. Furthermore, in other experiments, we determined that the SH2 domains of Slap and the Src family kinase Fyn bound to the PDGF receptor in vitro with similar affinities (data not shown). Collectively, these data suggest that Slap uses the same binding site(s) on the PDGF receptor as c-Src, although we cannot rule out that it might also associate with other phosphorylated tyrosine residues that were not tested here.
To investigate the effect of Slap overexpression, NIH3T3 cells were transfected with an expression vector encoding 976 Current Biology, Vol 8 No 17
Figure 2
Slap and Src share a binding site on the PDGF receptor. (a) Slap association with mutant PDGF receptors in vitro. HepG2 cells expressing an empty expression vector (vector) or various PDGF receptor mutants were metabolically labelled with 35 Smethionine/cysteine for 6 h, treated with PDGF (100 ng/ml) for 5 min and then lysed. After incubation with GST-Slap(N,SH3,SH2), the PDGF receptor was immunoprecipitated using anti-PDGF receptor (anti-PDGFR) antibody, subjected to SDS-PAGE and visualised by autoradiography. The various PDGF receptors tested were: wild type (WT); the R635 kinase-deficient receptor mutant (R635); the F5 mutant, which has five major tyrosine phosphorylation sites mutated to phenylalanine; the F581 mutant, which carries the Y581 to phenylalanine mutation; and the F5/581 mutant, which corresponds to the F5 mutant with the additional Y581 to phenylalanine mutation. (b) Inhibition of binding of Slap to the PDGF receptor by phosphotyrosine-containing peptides. Immobilised GST-Slap(N,SH3,SH2) was incubated with different peptides containing the indicated tyrosine residues (phosphorylated and unphosphorylated) before a lysate of insect cells expressing the human PDGF receptor was added. After washing, the presence of the bound receptor was detected by an in vitro kinase assay [6] . FLAG-epitope-tagged Slap (Slap-FLAG), and subsequently selected for G418 resistance. Surprisingly, no Slap-expressing colonies were obtained, although several colonies (495 per µg DNA) were obtained with the empty vector. Colonies were obtained when the adaptor proteins Grb2 (484 per µg DNA) and Shc (450 per µg DNA) were transfected. These observations suggest that, in contrast to other adaptor proteins, overexpression of Slap was either toxic or growth inhibitory for NIH3T3 fibroblasts. Transient expression by microinjection was used to investigate this further [8, 9] . Data from several experiments, when pooled and analysed, indicated that overexpression of Slap inhibited more than 90% of cells from entering S phase in response to PDGF, when compared with control cells (Figure 3 ). Microinjection of Shc and Grb2 did not inhibit DNA synthesis. (Figure 3a) . Slap inhibition required an intact SH2 domain, but not the SH3 domain (Figure 3b ). This effect was specific for the SH2 domain of Slap because a chimeric molecule in which the Slap SH2 domain was replaced by the amino-terminal SH2 domain of Gap -Slap-GAP(SH2) -was also not inhibitory ( Figure 3b ). Similar results were obtained when GST fusions of Slap were microinjected into fibroblasts (data not shown). Overexpression of Slap with an intact SH2 domain also inhibited the mitogenic response of cells to serum (Figure 3c,d ).
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Figure 3
Slap and Slap∆SH3 inhibit the mitogenic response induced by both PDGF and serum, whereas Shc, Grb2, Slap∆SH2 and Slap-GAP(SH2) have no effect. Quiescent Inhibition of Slap potentiates mitogenesis. Quiescent NIH3T3 cells were microinjected with an affinity-purified anti-Slap antiserum, or anti-Slap antiserum preincubated with the immunising peptide (pep), as indicated. Cells were then stimulated with a suboptimal concentration of (a) PDGF (5ng/ml) or (b) serum (2.5%) for 18 h, and DNA synthesis was measured as described in the legend to If inhibition of mitogen-induced DNA synthesis is the physiological role of Slap, then removal of Slap should potentiate signalling. To test this, cells were microinjected with the Slap antibody, and then stimulated with a suboptimal dose of PDGF or serum. We observed that more microinjected cells entered S phase than control cells (Figure 4a,b) . Preincubation of the antibody with the immunising peptide demonstrated that these potentiation effects were specific for Slap. We conclude that the endogenous level of Slap in NIH3T3 cells can influence whether the cells progress though the cell cycle in response to a particular concentration of growth factor.
It is not clear how Slap inhibits the cell cycle. Preliminary data indicate that Slap inhibition can be overcome by heterologous expression of Myc (S.R., unpublished observations) suggesting that Slap antagonises the Src pathway [10] . Negative regulation of receptor-activated signalling pathways may be a general theme in cell growth control. Other recent examples include FRNK (FAK-related nonkinase), the Cis family of proteins that regulate cytokine signalling, and the T-cell adaptor protein Cbl [11] [12] [13] [14] [15] [16] .
Materials and methods
Slap and various mutants were derived by PCR, tagged with a FLAG epitope, and then cloned into pcDNA3 (Invitrogen). Slap(GAPSH2) contains the amino-terminal SH2 domain of GAP in place of the Slap SH2 domain. Expression constructs encoding Myc-tagged Grb2 and Shc were a gift from Ben Margolis (University of Michigan). Rabbit antiSlap serum against the nine carboxy-terminal residues of the mouse Slap sequence was affinity-purified as described [9] . Fusion proteins were purified as described [17] . Other antibodies, immunoprecipitation techniques, kinase assays, and peptide and peptide competition methodology have been described previously [6, 18] . For microinjection analysis, NIH3T3 cells were seeded, synchronised and microinjected as described [19] . Plasmids (100 ng/ml) were injected into the nucleus 4-6 h before cell stimulation. Affinity-purified antibody (1-2 mg/ml) was injected into the cytoplasm. Cells were stimulated for 18 h with PDGF (25 ng/ml unless otherwise indicated) or FCS (10% unless otherwise indicated), in medium containing BrdU (Sigma; 0.1 mM). BrdU incorporation was measured as described [9] . For transfection, NIH3T3 cells were seeded into 6-well dishes and transfected with 2 µg DNA per well using lipofectamine (Gibco BRL) according to manufacturer's instructions. The cells were trypsinised 24 h later and placed in selection medium containing 0.4 mg/ml G418. After 2-3 weeks, the number of colonies were visualised and counted by staining with crystal violet. For PDGF receptor association assays, cell lysates made from PDGF-treated or PDGF-untreated HepG2 cells expressing mutant PDGF receptors [5] were incubated with GST-Slap(N,SH3,SH2) or GST-Src(SH2) for 2 h at 4°C. Pelleted beads were then washed, boiled in 1% SDS to elute the bound material, diluted to a final concentration of 0.1% SDS, and immunoprecipitated using an antibody against the PDGF receptor. Association of the PDGF receptor with Slap in fibroblasts was assayed from lysates of quiescent fibroblasts that had been stimulated with PDGF (50 ng/ml) for 5 min or left unstimulated.
